FDA Determines Regulatory Review Period for NOVOSEVEN Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for NOVOSEVEN, a human biological product, in accordance with patent extension regulations, following a submission to the US Department of Commerce.